- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 4 - Biomarkers in Bone Turnover and Immunoglobulin Expression
Dr Chernew leads the conversation to biomarkers in bone turnover and immunoglobulin expression.
Dr Chernew leads the conversation to biomarkers in bone turnover and immunoglobulin expression. Dr Kumar says the use of biomarkers can be very specific to a disease type. He analyzes the use of bone marrow and bone biomarkers for monitoring myeloma bone disease. He says there are both prognostic and predictive biomarkers which suit different purposes. There are also other emerging biomarkers that are being studied and explored.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More
